

ROCE Fund - September 2024

Investment objectives

- Long only fund that invests in European equities with a superior return on capital employed (ROCE) at attractive valuations.
- Bottom-up, research-intensive stock picking approach.
- Main objective is to seek a performance that exceeds that of its benchmark, MSCI EUROPE Net Total Return (dividends reinvested) over the recommended investment period of at least 5 years.
- Past performance is not a guarantee of future results.

Yearly performance v benchmarks and peers²

					20	24	Since
Year	2020*	2021	2022	2023	Sep	YTD	inception
ROCE Fund (G) ¹	17%	21%	(10%)	22%	1.1%	4%	62%
MSCI Europe Total Return	10%	25%	(9%)	16%	(0.4%)	12%	61%
Outperformance/(under)	7%	(4%)	(1%)	<u>6%</u>	1.5%	(7%)	1%
MSCI Europe Mid Total Return	17%	24%	(23%)	13%	0.5%	10%	39%
Outperformance/(under)	(1%)	(3%)	12%	9%	0.6%	(5%)	23%
Peers' index ²	11%	22%	(16%)	15%	(0.3%)	8%	40%
Outperformance ² /(under)	6%	(0%)	6%	7%	1.4%	(4%)	22.1%
% peers beaten ²	84%	47%	73%	97%	89%	22%	85%

^{* 2020} includes performance from inception date (September 28th, 2020) until December 31st, 2020.

(not of food) v MCCI Europa Total D

Performance since inception v benchmark and peers



	performance (net of fees) v MSCI Europe Total Return													T	
Year		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year	Inception
	ROCE Fund (G) ¹									(0.4%)	(5.6%)	20.1%	3.4%	16.6%	
2020	Outperformance/(under) v peers' index ²									(0.2%)	(1.1%)	6.7%	0.6%	5.7%	
	Outperformance/(under) v MSCI Europe Total Return									0.3%	(0.6%)	6.1%	1.0%	6.6%	
	ROCE Fund (G) ¹	0.6%	5.0%	8.3%	3.0%	3.2%	0.7%	(0.7%)	0.9%	(3.0%)	1.5%	(4.3%)	5.1%	21.3%	
2021	Outperformance/(under) v peers' index ²	1.4%	2.0%	3.0%	0.4%	1.0%	(1.1%)	(2.9%)	(1.7%)	0.2%	(2.4%)	(1.6%)	1.6%	(0.5%)	
	Outperformance/(under) v MSCI Europe Total Return	1.3%	2.5%	1.8%	0.9%	0.6%	(1.0%)	(2.6%)	(1.1%)	0.0%	(3.1%)	(1.8%)	(0.5%)	(3.8%)	
	ROCE Fund (G) ¹	(2.3%)	(3.4%)	(0.4%)	(0.1%)	0.0%	(8.3%)	6.2%	(4.8%)	(7.7%)	6.3%	7.9%	(2.4%)	(10.0%)	
2022	Outperformance/(under) v peers' index ²	3.6%	0.7%	(1.3%)	1.8%	1.3%	0.3%	(2.3%)	0.6%	(0.1%)	(0.1%)	1.7%	1.1%	6.5%	
	Outperformance/(under) v MSCI Europe Total Return	0.9%	(0.4%)	(1.2%)	0.5%	0.8%	(0.5%)	(1.4%)	0.1%	(1.4%)	0.1%	1.0%	1.1%	(0.5%)	
	ROCE Fund (G) ¹	9.6%	2.9%	(0.4%)	0.6%	(2.0%)	3.2%	3.4%	(1.9%)	(3.9%)	(5.8%)	8.6%	7.2%	22.1%	
2023	Outperformance/(under) v peers' index ²	2.3%	0.9%	(0.1%)	(0.4%)	(0.7%)	1.3%	1.7%	0.3%	(1.0%)	(1.2%)	1.0%	3.3%	7.6%	
	Outperformance/(under) v MSCI Europe Total Return	2.8%	1.1%	(0.3%)	(1.9%)	0.5%	0.8%	1.4%	0.6%	(2.3%)	(2.2%)	2.2%	3.5%	6.3%	
	ROCE Fund (G) ¹	(1.5%)	(0.0%)	4.3%	(0.9%)	7.6%	(7.6%)	1.8%	0.3%	1.1%				4.4%	62.3%
2024	Outperformance/(under) v peers' index ²	(2.7%)	(2.3%)	0.8%	1.1%	4.4%	(5.7%)	0.6%	(0.4%)	1.4%				(3.7%)	22.1%
	Outperformance/(under) v MSCI Europe Total Return	(3.0%)	(1.9%)	0.3%	(0.0%)	4.3%	(6.7%)	0.7%	(1.3%)	1.5%				(7.2%)	1.2%

Note: Chart on the right illustrates performance of ROCE Fund (class G net of fees) vits benchmark (MSCI Europe Net Total Return)

ROCE Fund was up 1.1% in September 2024, outperforming its benchmark, MSCI Europe which was down 0.4% over the same period.

Equity markets in September reflected a mix of optimism and uncertainty. On one hand, markets were supported by the Fed's larger than expected 50bps rate cut, but on the other hand, concerns over an economic slowdown and escalating tensions in the Middle East held back further optimism. In this environment, the ROCE Fund outperformed the MSCI Europe by 1.5%.

Our top performer for the month was **Watches of Switzerland**, the UK luxury watch and jewelry retailer, which appreciated by 22% following a reassuring trading update confirming its 2025 guidance. Additionally, the Chinese stimulus measures provided a boost to the luxury sector as a whole. We trimmed our position slightly on strength after having bought more on recent weakness. It is still in our top 10.

Our main detractor in September was **Kitron**, the Norwegian electronics manufacturing company, which fell by 18% after a profit warning due to destocking from several key customers. We have spoken with the CEO following this negative guidance revision and view this as a temporary setback. Kitron remains a quality compounder, generating a best-in-class 28% pre-tax ROCE, and benefits from long-term structural growth drivers. We are likely to increase our position in due course.

Lastly, we initiated a new position in **Forbo**, the Swiss industrial conglomerate operating in non-residential flooring products and manufacturing of conveyor belts. Although the company has faced challenges over the past two years due to cost inflation and weak end markets, it meets many of our investment criteria. Forbo boasts a pre-tax ROCE of 24%, a net cash balance sheet, and strong market share in its key segments. Its shareholder -friendly capital allocation, with 100% of free cash flow returned to shareholders over the past decade as well as its attractive valuation at 11x P/E (30% below long-term historical average) made this an appealing opportunity for us.

Our portfolio remains appealing, with a valuation of only 12x PE, representing a 20% discount compared to MSCI Europe, and it boasts a superior ROCE of 21%, 50% above market average.

As ROCE Fund celebrates its 4-year anniversary, we are proud to report that since inception, it has returned 62% net of fees or 13% annualised, outperforming both its benchmark and 85% of its peers². ROCE fund has also significantly grown its assets under management, fivefold from €22m at launch to €112m today.

Fund characteristics

AUMs:	€112m	Legal structure:	French SICAV – UCITS V
		0	
Currency:	EUR	Fund launch date:	28 September 2020
NAV (G share) as of 2 Oct 2024:	€1,626.6	Benchmark:	MSCI EUROPE Net Total Return
Number of positions:	54	Custodian/Valuation:	CIC/CMAM
Average weight:	1.7%	Auditor:	Mazars
Weight's standard deviation:	0.7%	Liquidity:	Daily before 12pm
Median market cap:	€3,307m	Management fee:	0.70% (G), 0.85% (H), 1.00% (I)
ISIN: FR0013518958 (G), FR0013518974	(H), FR0013519022 (I)	Performance fee:	10% above M7EU with HWM

ESG accreditations & characteristics

- Inclusive and rigorous ESG policy.
- Article 8 SFDR.
- 10% of performance fees redistributed to childhood cancer research.
- Signatory of principles for responsible investing.

Source: ROCE Capital, Bloomberg, CGP Conseils. ¹ Share class G net of management and performance fees.

² Peers' index defined by the average of 95 long only funds invested in European equities.


Solving Kids' Cancer



Portfolio key financial metrics



Portfolio breakdowns by country, sector (GICS) and market cap



Top 5 positions

Company name	Weight	Market cap	Country	Sector	ROCE	P/E
TRIGANO SA	3.3%	€2,266m	FRANCE	Consumer Discretionary	30%	6x
NEXITY	3.3%	€694m	FRANCE	Real Estate	12%	NA
EDENRED	3.1%	€8,522m	FRANCE	Financials	30%	17x
BENETEAU	3.1%	€797m	FRANCE	Consumer Discretionary	26%	15x
FUTURE PLC	2.7%	€1,348m	BRITAIN	Communication Services	16%	8x

Note: Data above (top 5 positions, portfolio breakdowns and key financial metrics) as of date of this report.

Key financial metrics based on median data for ROCE Fund and average data for MSCI Europe.

Contact

Name	Position	Email					
Matthieu Bordeaux-Groult	CEO/Development	mbg@rocecapital.com					
Michael Niedzielski	Fund manager	mn@rocecapital.com					
Management company: www.rocecapital.com		ROCE Capital SAS, 63, Avenue des Champs-Élysées, 75008 Paris, France Telephone: +33 1 55 27 27 90					
	1	Lower risk Higher risk					

2i SÉLECTION Le fonds révélateur de talents



This document should be read in conjunction with the prospectus and relevant KIIDs. The UCITS Fund does not benefit from any guarantee or protection, so the initial invested capital may not be fully repaid. The information contained in this document does not constitute any recommendation or investment proposal. This material has been prepared for information contained in this bean prepared for information appropses only. This document is nell her an offer to sell nor a solicitation of an offer to buy any securities or other investment product described herein. Product(s) described herein is/are not available to all persons in all geographic locations. There are significant risks associated with investment in the Fund. Investment may not be suitable for all investors and is intended for sophisticated investors who have fully understood the risks associated with nust be meet and carefully before any description to invest material basects of the Fund, which contains important information concerning risk factors, past performance, and material aspects of the Fund and which must be read carefully before any description to invest in will reeview a trun of all or part of their investment.

Lower potential yield Higher potential yield

This UCITS is classified in category 4 due to its exposure to international equity markets that may experience significant fluctuations. Indeed, the net asset value may be subject to variations induced by the maturity of the securities, the portfolio's sensitivity and the volatility of the equity market.